Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tecentriq Takes EU Lead In Triple-Negative Breast Cancer

Aug 29 2019

• By John Davis

Cycling — Roche is ahead of the field in triple-negative breast cancer • Source: Shutterstock

Related Content

Pipeline Watch: Phase II/III Start With Nipocalimab, Phase III With Verdiperstat

Aug 05 2019

Roche Wins Two French Early Access Programs In Breast Cancer

Aug 28 2019

Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

Jul 26 2019

Pipeline Watch: Phase III Read-Outs For Zanubrutinib, Surufatinib

Jun 24 2019

Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer

Mar 09 2019

Related Companies

Roche Holding AG

AstraZeneca PLC

Array BioPharma, Inc.

Merck & Co., Inc.

G1 Therapeutics Inc.

Additional Topics

Europe ImmunoOncology Approvals Commercial Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window